Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.

Abstract

With the increased use of tyrosine kinase inhibitors as successful therapy in selected malignancies, their adverse effects will grow, especially when combination therapy is used. We present a relatively young patient who was successfully treated with erlotinib and sunitinib for her metastatic non-small-cell lung cancer (NSCLC), but died because of the serious event of a necrotizing pancreatitis with severe hypocalcaemia, which we suppose to be an adverse event of the therapy used.